Literature DB >> 9267947

Relationship between leukocyte count and patient risk for excessive blood loss after cardiac surgery.

G J Despotis1, V Levine, L T Goodnough.   

Abstract

OBJECTIVE: To evaluate the relationship between leukocyte counts and risk for excessive blood loss after cardiac surgery when including numerous demographic, operative, and laboratory factors in the comparison.
DESIGN: A prospective, clinical evaluation.
SETTING: A point-of-care laboratory and the cardiac surgical unit of a university-affiliated tertiary center. PATIENTS: Patient-related and hematologic variables were measured, using blood specimens obtained from 89 hospitalized patients who underwent cardiac surgery involving cardiopulmonary bypass.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Demographic, operative, and transfusion-related data were recorded for each patient. Routinely obtained measurements of laboratory-based prothrombin time, partial thromboplastin time, complete blood count, and bleeding time were recorded. Hemoglobin concentration, platelet count, and red and white blood cell counts were measured with an on-site instrument before initiation (pre-cardiopulmonary bypass) and before discontinuation (end-cardiopulmonary bypass) of cardiopulmonary bypass. Hematocrit was calculated using recorded variables, and white blood cell percent change values were calculated using white blood cell counts from both periods, using the following formula: [(end-cardiopulmonary bypass - pre-cardiopulmonary bypass)/pre-cardiopulmonary bypass] x 100. When we excluded four patients who had a surgical source of post-cardiopulmonary bypass bleeding, significant (p < .0001) relationships were observed between white blood cell count (r2 = .46) and white blood cell percent change values (r2 = .71) and cumulative mediastinal chest tube drainage in the first 4 postoperative hours in 85 patients. Bayes theorem was used to evaluate the predictive ability of hematologic measurements in identifying patients with excessive bleeding (n = 24), defined as >1000 mL of cumulative chest tube drainage in the first 24 postoperative hours, when compared with patients without excessive bleeding (n = 61). Demographic and operative variables were similar between these patients except that patients with excessive bleeding required more red blood cell, platelet, and plasma transfusions during the postoperative interval. Significantly (p < .0001) greater white blood cell percent change values were obtained in the excessive bleeding cohort (119 +/- 93 percent change) when compared with patients without excessive bleeding (28 +/- 36 percent change).
CONCLUSIONS: On-site measurements of white blood cell count, as an index of the inflammatory response to extracorporeal circulation, may be useful in identifying patients at increased risk for excessive bleeding. Further studies are needed to examine whether white blood cell counts during multiple cardiopulmonary bypass periods may identify patients with an exaggerated inflammatory response to extracorporeal circulation. By using this information, physicians may be able to intervene with anti-inflammatory medications and blood preservation techniques.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9267947     DOI: 10.1097/00003246-199708000-00021

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  2 in total

1.  Hematological Changes in Patients Undergoing Coronary Artery Bypass Surgery: a Prospective Study.

Authors:  Sotir Lako; Teuta Dedej; Tatjana Nurka; Vera Ostreni; Aurel Demiraj; Roland Xhaxho; Edvin Prifti
Journal:  Med Arch       Date:  2015-06-10

2.  Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran: a real-world study.

Authors:  Wei Zhou; Tao Wang; Ling-Juan Zhu; Ming-Hua Wen; Li-Hua Hu; Xiao Huang; Chun-Jiao You; Ju-Xiang Li; Yan-Qing Wu; Qing-Hua Wu; Hui-Hui Bao; Xiao-Shu Cheng
Journal:  Chin Med J (Engl)       Date:  2019-09-20       Impact factor: 2.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.